NR1H4 and liver disorder: Fexaramine served as a starting point for the development of a series of FXR agonists aimed at treating liver diseases, as reported by Huang et al. in 2024.[127] These compounds were strategically developed to improve efficacy and selectivity, addressing the significant side effects reported in clinical trials for most existing FXR agonists.